Phase I/II Study Of Herceptin Combined With OSI-774 In The First-Line Treatment Of Metastatic Breast Cancer Associated With HER2/Neu Overexpression

Trial Profile

Phase I/II Study Of Herceptin Combined With OSI-774 In The First-Line Treatment Of Metastatic Breast Cancer Associated With HER2/Neu Overexpression

Completed
Phase of Trial: Phase I/II

Latest Information Update: 15 Apr 2016

At a glance

  • Drugs Erlotinib (Primary) ; Trastuzumab (Primary)
  • Indications Advanced breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 08 Apr 2016 Recommended Dose for Phase II added as primary endpoint hence trial focus changed from TU to TU + AR.
    • 17 Jun 2011 Trial phase changed from II to I/II as reported by ClinicalTrials.gov.
    • 17 Jun 2011 Planned end date changed from 1 Oct 2010 to 1 Oct 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top